← Back to Search

Immunosuppressant

Monoclonal Antibodies + Chemotherapy for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cardiovascular: LVEF at least 50%

Hepatic: Bilirubin no greater than 1.5 mg/dL, AST no greater than 84 U/L

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will use monoclonal antibodies to attack cancer cells while leaving healthy cells unharmed. The study will also combine this therapy with paclitaxel and cyclosporine to see if it is an effective treatment for patients with non-Hodgkin's lymphoma who have not responded to other treatments.

Who is the study for?

This trial is for adults with non-Hodgkin's lymphoma that hasn't responded to standard treatments. They must have a certain level of blood cells, heart and lung function, no other cancers in the past 5 years, not be pregnant or breastfeeding, and agree to use contraception. People can't join if they've had recent chemotherapy or radiotherapy.Check my eligibility

What is being tested?

The study is testing a combination therapy for non-Hodgkin's lymphoma involving a radiolabeled monoclonal antibody with paclitaxel (a chemotherapy drug) and cyclosporine (an immune system suppressant). It aims to see how effective this mix is at targeting and killing cancer cells.See study design

What are the potential side effects?

Possible side effects include reactions related to the monoclonal antibody such as fever or chills, low blood cell counts from paclitaxel leading to increased infection risk or bleeding problems, and cyclosporine may cause kidney issues or high blood pressure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My heart's pumping ability is normal or near normal.

Select...

My liver function tests are within normal limits.

Select...

My non-Hodgkin's lymphoma did not respond to the first round of chemotherapy.

Select...

My lung function tests are within the required range.

Select...

I am mostly able to care for myself and carry out daily activities.

Select...

My lymphoma tissue reacts to Lym-1 in tests.

Select...

I am 18 years old or older.

Select...

My bone marrow biopsy shows less than 25% involvement by NHL.

Select...

My kidney function is good, with creatinine below 1.5 mg/dL or clearance above 50 mL/min.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

911 Previous Clinical Trials

4,709,583 Total Patients Enrolled

9 Trials studying Lymphoma

765 Patients Enrolled for Lymphoma

Gerald L. DeNardo, MDStudy ChairUniversity of California, Davis

1 Previous Clinical Trials

1 Trials studying Lymphoma

Media Library

Cyclosporine (Immunosuppressant) Clinical Trial Eligibility Overview. Trial Name: NCT00009776 — Phase 1

Lymphoma Clinical Trial 2023: Cyclosporine Highlights & Side Effects. Trial Name: NCT00009776 — Phase 1

Cyclosporine (Immunosuppressant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00009776 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for patients to participate in this clinical experiment?

"Based on the clinicaltrials.gov entry for this trial, it appears that recruitment has stopped since its initial post date of March 1st 2001 and last edit from September 19th 2013. However, there are 1750 other studies presently looking to enroll patients."

Answered by AI